Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp WT
(NQ:
LEXXW
)
0.7484
UNCHANGED
Streaming Delayed Price
Updated: 3:12 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lexaria Bioscience Corp WT
< Previous
1
2
3
4
5
6
7
Next >
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
November 20, 2024
Via
ACCESSWIRE
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
November 14, 2024
Via
ACCESSWIRE
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
November 13, 2024
Via
ACCESSWIRE
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
November 07, 2024
Via
ACCESSWIRE
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
October 24, 2024
Via
ACCESSWIRE
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
October 22, 2024
Via
ACCESSWIRE
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
October 16, 2024
Via
ACCESSWIRE
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
October 09, 2024
Via
ACCESSWIRE
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
September 27, 2024
Via
ACCESSWIRE
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
October 15, 2024
Via
ACCESSWIRE
Lexaria Updates Current GLP-1 Market
October 08, 2024
Via
ACCESSWIRE
Lexaria Appoints Michael Shankman as Chief Financial Officer
October 01, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO
September 06, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Releases Strategic Letter from the Outgoing CEO
September 05, 2024
Via
ACCESSWIRE
Lexaria Welcomes Industry Veteran as New CEO
September 05, 2024
Via
ACCESSWIRE
First Results from Lexaria's Second GLP-1 Human Pilot Study
August 27, 2024
Via
ACCESSWIRE
Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
August 22, 2024
Via
ACCESSWIRE
Lexaria Enters a Material Transfer Agreement for DehydraTECH Research
September 03, 2024
Via
ACCESSWIRE
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
August 29, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’
August 27, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive 8-Week Body Weight Results from Ongoing Diabetes Animal Study
August 22, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
August 21, 2024
Via
ACCESSWIRE
Positive Results from Lexaria's Molecular Characterization Study
August 19, 2024
Via
ACCESSWIRE
Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
July 17, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Positive Results from Molecular Characterization Study
August 19, 2024
Via
CannabisNewsWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study
July 17, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Preparing For Strategic Growth
July 16, 2024
Via
ACCESSWIRE
Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
July 09, 2024
Via
ACCESSWIRE
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
July 08, 2024
Via
ACCESSWIRE
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
June 18, 2024
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
